you'll have to forgive Joanie she was up all night squeezing her ego..
Joanie to Jokoe; "Jokoemiah I can't sleep. Tell me again what the savages do to the women they capture."
well all looks good for expanded trials and indications but the being kept under a bushel PR from GERN sux. Either Janssen or Chippy better start sharing more soon or dem damn ambulance lawyers will start chasing porsches in the streets of Menlo park again
who's to say Janssen isn't setting these sites up for a wider IMET NCT01731951 MF expansion once this comparative study is concluded after interim data analysis for BTA designation application submission? Like you say everything will be in place for MF /IMET treatment. MF indication sweep later will be much easier to implement with existing sites given the already on going IMBARK High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor limited study of NCT02426086. Janssen wouldn't be continually expanding sites & spending money if the current data wasn't promising.
GERN is the autistic one in the bunch. We still have another 40% move upwards to break even with $5.10 in Dec. Most other bio techs have made up their losses from Jan.1
I never realized it was that high. GWBJ never ran the country it was Cheney/Haliburton behind the scenes that created the middle east Arab spring which has taken the world to the current apocalyptic edge.
my bet would be on Saunders; brain vs brawn. Most Americans wouldn't want a pres. functioning several quarters below their own IQ's. We had enough of Bush junior.
pretty well the same thing
Alien Gelgamek #$%$ is three feet wide and filled with razor-sharp teeth
OHRP just got their $30 price target updated.
up 8.57% on news. This one's even more of an elevator ride than GERN
GALE up 17%
TRXC up 7.6%
GERN up 6%
ACAD up 4.9%
"As for ET, John on a CC mention that it was not economical to go after ET because there to many competition for ET and a faster way for approval was to go after MF as an orphan drug" ...actually the deal with the FDA hold being lifted was that GERN would not pursue ET designations as there is a greater unmet medical need for a new product than is the case for diseases such as ET, for which survival is minimally affected by the disease. Probably an INCY clause in place. Subsequently Jansen's first new trial was an IMET's high risk MF patients trial previously treated with Jakafi; a major game changer for this space and IMET directly comparing both drug results. If data supports Mayo's MF results, Imet will become the standard for MF treatment under BAT. (7 months of data collected so far from Oct 2015 1ST infusion)
Perhaps Chippy wasn't invited to the presentation.
Must be nice drawing a $1+ salary in abstentia. Maybe his next public presentation should be on "how to run a biotech as one's personal cash cow"
Okay I'll take the bait....so tell me why was this alleged 'player' was a no show?